研究者詳細 - 木下　翔太郎

BioScience Trends （International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)） [Epub ahead of print] （ 5 ） 492 - 494 2024年10月

共著, 査読有り, ISSN 1881-7815

Access to Document (DOI)

Assessment of Stress and Well-Being of Japanese Employees Using Wearable Devices for Sleep Monitoring Combined With Ecological Momentary Assessment: Pilot Observational Study

Shotaro Kinoshita, Sayaka Hanashiro, Shiori Tsutsumi, Kiko Shiga, Momoko Kitazawa, Yasuyo Wada, Jun Inaishi, Kazuhiro Kashiwagi, Toshikazu Fukami, Yasumasa Mashimo, Kazumichi Minato, Taishiro Kishimoto

JMIR Formative Research （JMIR Publications Inc.） [in press] e49396 2024年05月

共著, 査読有り

Access to Document (DOI)

Ageing population in Japan: Immediate shake-up in healthcare required

Shotaro Kinoshita, Taishiro Kishimoto

QJM: An International Journal of Medicine （Oxford University Press (OUP)） [Epub ahead of print] hcae097 2024年05月

共著, 査読有り, ISSN 1460-2725

Access to Document (DOI)

Anti-obesity drugs, eating disorders, and thinness among Japanese young women

Shotaro Kinoshita, Taishiro Kishimoto

The Lancet Diabetes & Endocrinology （Elsevier BV） 12 （ 2 ） 90 - 92 2024年02月

共著, 査読有り, ISSN 2213-8587

Access to Document (DOI)

Updating the Japanese healthcare system to meet the needs of an aging society

Shotaro Kinoshita, Taishiro Kishimoto

JMA Journal [In press] 2024年

共著, 査読有り

Associations between glycemic variability, sleep quality, and daily steps in subjects without diabetes using wearable devices

Jun Inaishi, Kazuhiro Kashiwagi, Shotaro Kinoshita, Yasuyo Wada, Sayaka Hanashiro, Kiko Shiga, Momoko Kitazawa, Shiori Tsutsumi, Hiroyuki Yamakawa, Taishiro Kishimoto

Metabolism Open 20 100263 - 100263 2023年12月

共著, 査読有り, ISSN 2589-9368

Access to Document (DOI)

Live two-way video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive disorder: A 24-week randomized controlled trial

Taishiro Kishimoto, Shotaro Kinoshita, Momoko Kitazawa, Akitoyo Hishimoto, Takeshi Asami, Akira Suda, Shogyoku Bun, Toshiaki Kikuchi, Mitsuhiro Sado, Akihiro Takamiya, Masaru Mimura, Yasunori Sato, Ryo Takemura, Kengo Nagashima, Takashi Nakamae, Yoshinari Abe, Tetsufumi Kanazawa, Yasuo Kawabata, Hiroaki Tomita, Koichi Abe, Seiji Hongo, Hiroshi Kimura, Aiko Sato, Hisashi Kida, Kei Sakuma, Michitaka Funayama, Naoya Sugiyama, Kousuke Hino, Toru Amagai, Maki Takamiya, Hideyuki Kodama, Kenichi Goto, Shuichiro Fujiwara, Hisanobu Kaiya, Kiichiro Nagao

Psychiatry and Clinical Neurosciences [Epub ahead of print] （ 4 ） 220 - 228 2023年12月

共著, 筆頭著者, 査読有り

Access to Document (DOI)

Psychiatrists’ Perspectives on Advantages, Disadvantages and Challenging for Promotion Related to Telemedicine: Japan’s Clinical Experience During COVID-19 Pandemic

Shotaro Kinoshita, Momoko Kitazawa, Yoshinari Abe, Akira Suda, Takashi Nakamae, Tetsufumi Kanazawa, Hiroaki Tomita, Akitoyo Hishimoto, Taishiro Kishimoto

Journal of Technology in Behavioral Science （Springer Science and Business Media LLC） [Epub ahead of Print] 532 - 541 2023年12月

共著, 査読有り

Access to Document (DOI)

Assessment of glycemic variability and lifestyle behaviors in healthy nondiabetic individuals according to the categories of body mass index

Kazuhiro Kashiwagi, Jun Inaishi, Shotaro Kinoshita, Yasuyo Wada, Sayaka Hanashiro, Kiko Shiga, Momoko Kitazawa, Shiori Tsutsumi, Hiroyuki Yamakawa, Junichiro Irie, Taishiro Kishimoto

PLOS ONE （Public Library of Science (PLoS)） 18 （ 10 ） e0291923 - e0291923 2023年10月

共著, 査読有り

Background

There are limited data about the association between body mass index (BMI), glycemic variability (GV), and life-related factors in healthy nondiabetic adults.

Methods

This cross-sectional study was carried out within our ethics committee-approved study called “Exploring the impact of nutrition advice on blood sugar and psychological status using continuous glucose monitoring (CGM) and wearable devices”. Prediabetes was defined by the HbA1c level of 5.7–6.4% and /or fasting glucose level of 100–125 mg/dL. Glucose levels and daily steps were measured for 40 participants using Free Style Libre and Fitbit Inspire 2 under normal conditions for 14 days. Dietary intakes and eating behaviors were assessed using a brief-type self-administered dietary history questionnaire and a modified questionnaire from the Obesity Guidelines.

Results

All indices of GV were higher in the prediabetes group than in the healthy group, but a significant difference was observed only in mean amplitude of glycemic excursions (MAGE). In the multivariate analysis, only the presence of prediabetes showed a significant association with the risk of higher than median MAGE (Odds, 6.786; 95% CI, 1.596–28.858; P = 0.010). Additionally, the underweight (BMI < 18.5) group had significantly higher value in standard deviation (23.7 ± 3.5 vs 19.8 ± 3.7 mg/dL, P = 0.038) and coefficient variability (22.6 ± 4.6 vs 18.4 ± 3.2%, P = 0.015), compared to the normal group. This GV can be partially attributed to irregularity of eating habits. On the contrary, the overweight (BMI ≥ 25) group had the longest time above the 140 or 180 mg/dL range, which may be due to eating style and taking fewer steps (6394 ± 2337 vs 9749 ± 2408 steps, P = 0.013).

Conclusions

Concurrent CGM with diet and activity monitoring could reduce postprandial hyperglycemia through assessment of diet and daily activity, especially in non- normal weight individuals.

Access to Document (DOI)

Conspiracy Theories, Anti-Science, and Anti-Medicine in the COVID-19 Pandemic

Shotaro Kinoshita

CBEL Report （東京大学生命倫理連携研究機構） 6 （ 1 ） 80 - 81 2023年07月

単著, 査読有り

Telepsychiatry vs. Face-to-Face Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Hagi Katsuhiko, Kurokawa Shunya, Takamiya Akihiro, Fujikawa Mayu, Kinoshita Shotaro, Iizuka Mari, Furukawa Shota, Eguchi Yoko, Kishimoto Taishiro

The British Journal of Psychiatry (in press) （ 3 ） 407 - 414 2023年05月

共著, 査読有り

BACKGROUND: The COVID-19 pandemic has transformed healthcare significantly and telepsychiatry is now the primary means of treatment in some countries. AIMS: To compare the efficacy of telepsychiatry and face-to-face treatment. METHOD: A comprehensive meta-analysis comparing telepsychiatry with face-to-face treatment for psychiatric disorders. The primary outcome was the mean change in the standard symptom scale scores used for each psychiatric disorder. Secondary outcomes included all meta-analysable outcomes, such as all-cause discontinuation and safety/tolerability. RESULTS: We identified 32 studies (n = 3592 participants) across 11 mental illnesses. Disease-specific analyses showed that telepsychiatry was superior to face-to-face treatment regarding symptom improvement for depressive disorders (k = 6 studies, n = 561; standardised mean difference s.m.d. = -0.325, 95% CI -0.640 to -0.011, P = 0.043), whereas face-to-face treatment was superior to telepsychiatry for eating disorder (k = 1, n = 128; s.m.d. = 0.368, 95% CI 0.018-0.717, P = 0.039). No significant difference was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 26, n = 2290; P = 0.248). Telepsychiatry had significantly fewer all-cause discontinuations than face-to-face treatment for mild cognitive impairment (k = 1, n = 61; risk ratio RR = 0.552, 95% CI 0.312-0.975, P = 0.040), whereas the opposite was seen for substance misuse (k = 1, n = 85; RR = 37.41, 95% CI 2.356-594.1, P = 0.010). No significant difference regarding all-cause discontinuation was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 27, n = 3341; P = 0.564). CONCLUSIONS: Telepsychiatry achieved a symptom improvement effect for various psychiatric disorders similar to that of face-to-face treatment. However, some superiorities/inferiorities were seen across a few specific psychiatric disorders, suggesting that its efficacy may vary according to disease type.

Access to Document (DOI)

Development of medical device software for the screening and assessment of depression severity using data collected from a wristband-type wearable device: SWIFT study protocol

Taishiro Kishimoto, Shotaro Kinoshita, Toshiaki Kikuchi, Shogyoku Bun, Momoko Kitazawa, Toshiro Horigome, Yuki Tazawa, Akihiro Takamiya, Jinichi Hirano, Masaru Mimura, Kuo-ching Liang, Norihiro Koga, Yasushi Ochiai, Hiromi Ito, Yumiko Miyamae, Yuiko Tsujimoto, Kei Sakuma, Hisashi Kida, Gentaro Miura, Yuko Kawade, Akiko Goto, Fumihiro Yoshino

Frontiers in Psychiatry （Frontiers Media SA） 13 1025517 - 1025517 2022年12月

共著, 査読有り

INTRODUCTION: Few biomarkers can be used clinically to diagnose and assess the severity of depression. However, a decrease in activity and sleep efficiency can be observed in depressed patients, and recent technological developments have made it possible to measure these changes. In addition, physiological changes, such as heart rate variability, can be used to distinguish depressed patients from normal persons; these parameters can be used to improve diagnostic accuracy. The proposed research will explore and construct machine learning models capable of detecting depressive episodes and assessing their severity using data collected from wristband-type wearable devices. METHODS AND ANALYSIS: Patients with depressive symptoms and healthy subjects will wear a wristband-type wearable device for 7 days; data on triaxial acceleration, pulse rate, skin temperature, and ultraviolet light will be collected. On the seventh day of wearing, the severity of depressive episodes will be assessed using Structured Clinical Interview for DSM-5 (SCID-5), Hamilton Depression Rating Scale (HAMD), and other scales. Data for up to five 7-day periods of device wearing will be collected from each subject. Using wearable device data associated with clinical symptoms as supervisory data, we will explore and build a machine learning model capable of identifying the presence or absence of depressive episodes and predicting the HAMD scores for an unknown data set. DISCUSSION: Our machine learning model could improve the clinical diagnosis and management of depression through the use of a wearable medical device. CLINICAL TRIAL REGISTRATION: [https://jrct.niph.go.jp/latest-detail/jRCT1031210478], identifier [jRCT1031210478].

Access to Document (DOI)

我が国における大麻草由来の成分を用いた製品の適正な普及に向けた課題―Cannabidiol(CBD)に焦点をあてて―

木下翔太郎

保健医療科学（国立保健医療科学院） 71 （ 5 ） 440 - 446 2022年12月

単著, 査読有り

デジタルツイン技術の医療・健康分野における応用可能性と倫理的・法的・社会的課題（ELSI）

木下翔太郎

情報通信政策研究（総務省情報通信政策研究所） 6 （ 1 ） Ⅱ-1 - Ⅱ-21 2022年11月

単著, 査読有り

Access to Document (DOI)

Advantages and disadvantages of the long-term use of telepsychiatry

Shotaro Kinoshita, Taishiro Kishimoto

Irish Journal of Psychological Medicine （Cambridge University Press (CUP)） [Epub ahead of print] （ 3 ） 1 - 2 2022年05月

共著, 査読有り

Access to Document (DOI)

遠隔医療における規制はどこまで必要なのか

木下翔太郎

CBEL Report （東京大学生命・医療倫理教育研究センター） 4 （ 2 ） 36 - 37 2022年03月

共著, 査読有り

COVID-19 パンデミックにおける17の国と地域の精神科遠隔医療規制の変化

木下翔太郎

国際医療福祉大学 2022年03月

共著, 査読有り

COVID-19 パンデミック前後における遠隔医療の普及と課題―政策の観点から

木下翔太郎

情報通信政策研究（総務省情報通信政策研究所） 5 （ 1 ） 49 - 67 2021年10月

研究論文（学術雑誌）, 単著, 査読有り

Access to Document (DOI)

Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial (J-PROTECT): Rationale, design, and methodology

Taishiro Kishimoto, Shotaro Kinoshita, Shogyoku Bun, Yasunori Sato, Momoko Kitazawa, Toshiaki Kikuchi, Mitsuhiro Sado, Akihiro Takamiya, Masaru Mimura, Takashi Nakamae, Yoshinari Abe, Tetsufumi Kanazawa, Yasuo Kawabata, Hiroaki Tomita, Koichi Abe, Akitoyo Hishimoto, Takeshi Asami, Akira Suda, Yoshinori Watanabe, Toru Amagai, Kei Sakuma, Hisashi Kida, Michitaka Funayama, Hiroshi Kimura, Aiko Sato, Shuichiro Fujiwara, Kiichiro Nagao, Naoya Sugiyama, Maki Takamiya, Hideyuki Kodama, Takaharu Azekawa, on behalf of, the, J-PROTECT collaborators

Contemporary Clinical Trials （Elsevier） 111 106596 - 106596 2021年10月

研究論文（学術雑誌）, 共著, 査読有り

INTRODUCTION: The COVID-19 pandemic has had a profound impact on the mental health of people around the world. Anxiety related to infection, stress and stigma caused by the forced changes in daily life have reportedly increased the incidence and symptoms of depression, anxiety disorder and obsessive-compulsive disorder. Under such circumstances, telepsychiatry is gaining importance and attracting a great deal of attention. However, few large pragmatic clinical trials on the use of telepsychiatry targeting multiple psychiatric disorders have been conducted to date. METHODS: The targeted study cohort will consist of adults (>18 years) who meet the DSM-5 diagnostic criteria for either (1) depressive disorders, (2) anxiety disorders, or (3) obsessive-compulsive and related disorders. Patients will be assigned in a 1:1 ratio to either a "telepsychiatry group" (at least 50% of treatments to be conducted using telemedicine, with at least one face-to-face treatment [FTF] within six months) or an "FTF group" (all treatments to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The study will utilize a master protocol design in that there will be primary and secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual disorder group. DISCUSSION: This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic on the practice of psychiatry. TRIAL REGISTRATION: jRCT1030210037, Japan Registry of Clinical Trials (jRCT).

Access to Document (DOI)

Current status and challenges of the dissemination of telemedicine in Japan after the start of the COVID-19 pandemic

Shotaro Kinoshita, Taishiro Kishimoto

Telemedicine and e-Health （Mary Ann Liebert, Inc.） (in press) （ 8 ） 1220 - 1224 2021年10月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

オンライン診療の適正な普及に関するヒアリング調査 ―現状把握と課題分析―

木下翔太郎, 成瀨浩史, 吉村健佑, 岸本泰士郎, 榎戸芙佐子, 押淵英弘, 兼子幸一, 瀬戸秀文, 辻本哲士, 長尾喜一郎, 三野進, 村田昌彦, 米田博, 稲垣中

精神神経学雑誌（日本精神神経学会） 124 （ 1 ） 16 - 27 2021年08月

研究論文（学術雑誌）, 共著, 査読有り

Camptocormia Secondary to Antipsychotic-associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography

Yuki Mashima, Hiroyuki Uchida, Shotaro Kinoshita, Yuki Arita, Akira Ninomiya, Masaru Mimura, Takahito Uchida

Journal of Clinical Psychopharmacology （Ovid Technologies (Wolters Kluwer Health)） Publish Ahead of Print （ 5 ） 608 - 610 2021年07月

研究論文（学術雑誌）, 共著, 査読有り, ISSN 0271-0749

Access to Document (DOI)

遠隔医療の普及における信頼の重要性

木下翔太郎

CBEL Report （東京大学生命・医療倫理教育研究センター） 3 （ 2 ） 12 - 13 2021年02月

共著, 査読有り

Changes in Telepsychiatry Regulations during the COVID-19 Pandemic: 17 Countries and Regions' Approaches to an Evolving Healthcare Landscape

Kinoshita S., Cortright K., Crawford A., Mizuno Y., Yoshida K., Hilty D., Guinart D., Torous J., Correll C.U., Castle D.J., Rocha D., Yang Y., Xiang Y.T., Kølbæk P., Dines D., Elshami M., Jain P., Kallivayalil R., Solmi M., Favaro A., Veronese N., Seedat S., Shin S., De Pablo G.S., Chang C.H., Su K.P., Karas H., Kane J.M., Yellowlees P., Kishimoto T.

Psychological Medicine （Psychological Medicine） 52 （ 13 ） 1 - 8 2020年

研究論文（学術雑誌）, 共著, 査読有り, ISSN 00332917

Background: During the COVID-19 pandemic, the use of telemedicine as a way to reduce COVID-19 infections was noted and consequently deregulated. However, the degree of telemedicine regulation varies from country to country, which may alter the widespread use of telemediine. This study aimed to clarify the telepsychiatry regulations for each collaborating country/region before and during the COVID-19 pandemic. Methods: We used snowball sampling within a global network of international telepsychiatry experts. Thirty collaborators from 17 different countries/regions responded to a questionnaire on barriers to the use and implementation of telepsychiatric care, including policy factors such as regulations and reimbursement at the end of 2019 and as of May 2020. Results: Thirteen of 17 regions reported a relaxation of regulations due to the pandemic; consequently, all regions surveyed stated that telepsychiatry was now possible within their public healthcare systems. In some regions, restrictions on prescription medications allowed via telepsychiatry were eased, but in 11 of the 17 regions, there were still restrictions on prescribing medications via telepsychiatry. Lower insurance reimbursement amounts for telepsychiatry consultations versus in-person consultations were reevaluated in 4 regions, and consequently, in 15 regions telepsychiatry services were reimbursed at the same rate (or higher) than in-person consultations during the COVID-19 pandemic. Conclusions: Our results confirm that, due to COVID-19, the majority of countries surveyed are altering telemedicine regulations that had previously restricted the spread of telemedicine. These findings provide information that could guide future policy and regulatory decisions, that facilitate greater scale and spread of telepsychiatry globally.